EPO published patent application EP4232119A1 for Insulet Corporation's insulin pump technology featuring site health monitoring and blood glucose control functionality for aid systems. The application was published March 25, 2026, with IPC classification A61M 5/142. Insulet Corporation is listed as the applicant with inventor Rangarajan Narayanaswami. The patent designates 37 European states including major markets such as Germany, France, United Kingdom, Italy, and Spain.

This patent publication does not create compliance obligations. For competitors in the insulin pump or diabetes management device market, this publication establishes prior art as of the filing date. Medical device manufacturers developing similar infusion systems should review the claims to assess potential freedom-to-operate implications. Legal and IP teams may need to update patent monitoring protocols to track this Insulet filing.